L-Arginine normalizes coronary vasomotion in long-term smokers.
about
Coronary microvascular dysfunction in women with nonobstructive ischemic heart disease as assessed by positron emission tomographyQuantitative myocardial perfusion imaging with a MR cold pressor test.L-arginine in cardiovascular disease: dream or reality?Effects of vitamin C on intracoronary L-arginine dependent coronary vasodilatation in patients with stable angina.Role of PET in the evaluation and understanding of coronary physiology.Noninvasive assessment of coronary microvascular function in women at risk for ischaemic heart disease.Arginine metabolism and nutrition in growth, health and diseaseCoronary vasomotor function assessed by positron emission tomography.Anatomy and physiology of coronary blood flow.PET and PET/CT in cardiovascular disease.Quantitative PET/CT measures of myocardial flow reserve and atherosclerosis for cardiac risk assessment and predicting adverse patient outcomes.Arginine and nitric oxide synthase: regulatory mechanisms and cardiovascular aspects.Antagonist molecules in the treatment of anginaThoracic fat volume is independently associated with coronary vasomotion.Oral L-arginine administration attenuates postprandial endothelial dysfunction in young healthy males.L-arginine ameliorates the abnormal sympathetic response of the dysfunctional human coronary microvasculature.Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes.Early insights of cardiac risk and treatment response with quantitative PET monitoring of coronary-specific endothelial dysfunction and myocardial perfusion reserve.
P2860
Q33651077-FF8077AB-BCEB-46F1-992F-D934D4900B81Q33918614-271EEE57-BBED-4467-B469-4C19D10CDBEDQ35055189-4F12C1CF-F973-40D0-8B9A-45AAD07C1F93Q35584813-936A9368-E684-4DBF-8178-A7CD1865228DQ36017117-F60D88A9-2CBF-4B7E-9E2F-B6349AA41056Q36979964-1FB4E92B-72AF-4C86-93B8-22CB7B7431FAQ37179500-29C0AF43-C47D-474E-81E1-2C38B3A366A7Q37638427-853F874E-6D9D-45C5-B9A6-A82869A034FBQ37762484-9D65D894-C9A5-40F8-AD1A-1122582CEAD8Q37896144-CEF61D32-306B-40C8-AE66-8EE1D0102710Q38080503-9014B577-9AF6-439C-9970-9DF271795961Q38112398-8B18FE6F-C571-49A9-989F-FDF7F766FAD8Q38139089-9447470C-9B47-4E05-996D-D3DF9D90F281Q38973278-0B7A771D-E595-46CA-80C9-5185368FE03EQ43778497-8FBB4EA4-4E46-4ED7-9766-3E518E763406Q44753295-A5D72EA4-1A1B-4945-A807-D29FEFB2D817Q44780008-3D189B67-E4A7-49A5-959C-E415A307F4B1Q53265083-5DB53DDD-5E4A-4890-9AF1-541973157580
P2860
L-Arginine normalizes coronary vasomotion in long-term smokers.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
L-Arginine normalizes coronary vasomotion in long-term smokers.
@en
L-Arginine normalizes coronary vasomotion in long-term smokers.
@nl
type
label
L-Arginine normalizes coronary vasomotion in long-term smokers.
@en
L-Arginine normalizes coronary vasomotion in long-term smokers.
@nl
prefLabel
L-Arginine normalizes coronary vasomotion in long-term smokers.
@en
L-Arginine normalizes coronary vasomotion in long-term smokers.
@nl
P2093
P356
P1433
P1476
L-Arginine normalizes coronary vasomotion in long-term smokers.
@en
P2093
P304
P356
10.1161/01.CIR.99.4.491
P407
P577
1999-02-01T00:00:00Z